Tag: CSL Behring
CSL’s post-heart attack drug fails in phase III trial causing drop in stocks
CSL’s post-heart attack drug fails in phase III trial causing drop in stocks
Read More
CSL’s Hemgenix becomes first hemophilia B gene therapy approved in EU
NETHERLANDS — The European Commission has approved CSL and uniQure’s gene therapy Hemgenix,...
Read More
FDA approves first gene therapy for hemophilia B, to retail at US$3.5M
USA — The Food and Drug Administration approved the first gene therapy for a type of hemophilia,...
Read More
CSL inaugurates new US$150m R&D facility in Germany
GERMANY -ASX-listed CSL, a leading global biotechnology company, has inaugurated its new €150...
Read More
LATEST DIGITAL MAGAZINE
